KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy

Drug Category: Array
Conference Category: Array
Lead Author: Dorsey, Mato, et al.
Published Date: 05/03/2017
Download Link: /wp-content/uploads/2019/03/ASCO%202017%20Dorsey%20Final.PDF
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top